• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

CPH Share Price Up on Completed Halucenex Acquisition (ASX:CPH)

Like 0

By Lachlann Tierney, Thursday, 15 July 2021

The Creso Pharma [ASX:CPH] share price jumped 8% after completing the acquisition of Canadian psychedelics company Halucenex Life Sciences.

The Creso Pharma Ltd [ASX:CPH] share price jumped 8% after completing the acquisition of Canadian psychedelics company Halucenex Life Sciences.

Creso says the acquisition gains access to a global market for psychedelic medicines worth an estimated US$100 billion.

CPH shares were up as much as 11.5% in early trade on the news. Pulling back somewhat in midday trade, the pot stock was still up 8% at time of writing.

Today’s gains contrast with Creso’s recent share price performance, having dropped 20% since the start of 2021.

Despite a sluggish year so far, CPH shares are still up 350% over the last 12 months.

ASX CPH - Creso Pharma Share Price ChartSource: Tradingview.com

Target acquired

Target acquisition no more.

After weeks of prefacing Halucenex updates with ‘target acquisition company’, Creso finally obtained its target.

In Creso’s view, the completion of this much-discussed transaction marks an ‘important milestone’, as it grants CPH access to the psychedelic-assisted psychotherapy sector and unlocks a ‘number of opportunities for the company in the near term.’

Creso PharmaSource: Company presentation

Halucenex Founder and CEO Bill Fleming thought that with Creso acquiring his firm, ‘we will be able to expedite our clinical trial and potential product development strategies which will unlock significant value for shareholders.’

CPH Share Price ASX outlook

When analysing pot stocks, it is informative to look at the performance of the wider industry.

For instance, the Global X Cannabis ETF (POTX) is one of the largest cannabis-themed ETFs on the market.

It is also exposed to the global cannabis industry, seeking to invest in companies worldwide and across the supply chain.

The ETF is currently trading down 55% from its 52-week high, although it is up 20% year-to-date.

Bloomberg - ETF and POTX TradingSource: Bloomberg

POTX trading down from its 52-week peak echoes Creso’s situation, with CPH itself currently down more than 60% from its 52-week high.

This could be partly explained by the inevitable retracing that followed a vertical spike last December.

CPH shares went from 5 cents on 1 December 2020 to more than 30 cents a mere fortnight or so later.

Not often can such frenzy be sustained, and Creso’s negative performance year-to-date may result from last year’s optimism cooling off.

That said, today’s healthy spike suggests investors are feeling positive about Creso finally completing the long-awaited acquisition.

Bullish investors may argue that with Halucenex having a strong presence in Canada — a solid cannabis market — Halucenex’s acquisition will offer commercially beneficial synergies.

Creso itself said today it would now leverage the expertise of Halucenex to ‘expedite product development initiatives, ongoing R&D and potential market entries.’

Pot stocks can be volatile, but the wider cannabis and psychedelic trend is one worth following.

If you’re looking for more insights into the sector and pot stocks in particular, then check out our latest free report, which discusses three pot stocks worth looking at right now.

Get your free copy here.

Regards,

Lachlann Tierney,

For Money Morning

PS: Our publication Money Morning is a fantastic place to start on your investment journey. We talk about the big trends driving the most innovative stocks on the ASX. Learn all about it here

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Lachlann Tierney

Lachlann’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • Australia ain’t the USA…and that’s great!
    By Callum Newman

    The outlook for Australia and the ASX are very different to the US and US shares. Here’s why…

  • The biggest infrastructure spending boom in history just kicked off
    By Nick Hubble

    Did governments screw up our gas supply? According to some sources in the industry, a rather similar thing happened to our electricity and water industry.

  • You Read it Here First: Great Asset Rotation Underway
    By James Cooper

    Media is swirling on the great asset transition taking place from the banks to the miners. But James Cooper made this prediction months ago in Mining Memo. Are you taking advantage?

Primary Sidebar

Latest Articles

  • Australia ain’t the USA…and that’s great!
  • The biggest infrastructure spending boom in history just kicked off
  • You Read it Here First: Great Asset Rotation Underway
  • The sector primed to fly into 2026
  • OpenAI and Microsoft Divorce?: Why this could be good for you

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988